Annex 16EU GMP Annex 16 — Certification by a Qualified Person and Batch Release

EU GMP Annex 16 addresses certification by a Qualified Person, or QP, and batch release of medicinal products. The current Commission listing identifies the Annex dated 12 October 2015, with a coming-into-operation date of 15 April 2016. It is part of the EU GMP Guide and must be read with the applicable legal framework, authorization and product context. It is not a software certification scheme or a generic quality-manager qualification.

The Annex distinguishes checking manufacture and testing, QP certification, and transfer to saleable stock or export. Those activities can occur at different sites and involve different people, but they must remain connected. A completed laboratory test, warehouse status change or internal quality review is not automatically the QP certification act. The evidence and authority for each decision need to be explicit.

The underlying QP duties are legal obligations; Annex 16 explains GMP expectations for performing them. For human medicinal products, Article 51 of Directive 2001/83/EC is a central legal reference. The Annex's historical legal-basis text includes veterinary provisions; do not use that historical citation alone as a complete statement of current veterinary law. Apply the current framework relevant to the product and jurisdiction.

The Annex describes certification and release within the EU for human and veterinary medicinal products holding a marketing authorization or made for export, with principles applicable to investigational products subject to differences in legal provisions. It expressly does not provide guidance on Official Control Authority Batch Release, or OCABR. That exclusion does not mean QP certification is irrelevant where OCABR also applies.

Define whether the product is authorized, investigational, imported or made for export, and identify the relevant manufacturing or importation authorization. Different circumstances affect the evidence and legal duties. A single company-wide checklist should not silently erase those differences. Where current law or specialized guidance differs, obtain the relevant analysis rather than treating the Annex as the only applicable document.

QP certification concerns a medicinal product batch and the QP's accountable decision. It must not be confused with certification of a quality management system, an individual software product, or a supplier. An article about Annex 16 does not establish that a vendor, customer or site is EU GMP certified. Claims of actual authorization or certification require their own evidence.

Annex 16 expects the full manufacturing and distribution chain to be documented and available to the QP, including relevant subcontractors and critical operations. A supply-chain diagram is useful when it preserves the actual relationships: starting materials, manufacturing stages, testing sites, importation and certification responsibilities. A decorative flowchart naming only company headquarters does not provide that understanding.

For each relevant site or activity, identify the authorization or qualification basis, responsibility, technical agreement and evidence available for the batch. Include outsourced activities that can affect quality. The QP needs sufficient assurance concerning the chain; a summary statement that all suppliers are approved may not explain the basis for an important outsourced operation.

Keep the diagram and associated responsibilities current when a testing laboratory, manufacturing site, transport arrangement or outsourced step changes. Assess the impact on the marketing authorization and GMP responsibilities as applicable. This is an evidence-design recommendation based on the Annex's expectations, not an assertion that every supply chain has the same sites or a universal required diagram format.

The Annex distinguishes QP certification from confirmations concerning defined manufacturing or testing steps. A QP at another site can provide a confirmation of the responsibilities performed there. Formal arrangements should identify the scope of each QP's responsibility and how the certifying QP relies on the relevant confirmations. A partial confirmation must not be described as final certification of the finished batch.

Document responsibility allocation in an agreed arrangement and maintain the information needed to support it. Address who reviews deviations, changes, laboratory results, site assessments and unresolved issues. Tasks can be performed by competent personnel or third parties, but the certifying QP's responsibilities are not removed merely because a checklist was completed elsewhere.

The marketing authorization holder's responsibility for the product over its lifecycle is distinct from the QP's batch-specific responsibilities. Manufacturing, QC, quality assurance, regulatory personnel and distribution personnel each supply relevant evidence or perform controlled steps. A useful organization avoids both extremes: expecting the QP personally to perform every technical task, and assuming delegated tasks eliminate the QP's need for assurance.

The evidence supporting certification should connect the batch to its authorized product, manufacturing and testing history, specifications and relevant assessments. The Annex's section 1.7 addresses matters including GMP conformity, the documented supply chain, audit availability, marketing-authorization conformity, validation status, completed records, quality-control results, stability information, changes, investigations and distribution arrangements. Read the actual provisions rather than replacing them with this summary.

A dossier index can help retrieve those items, but it is not evidence by itself. Check the documents behind each entry and distinguish completed review from pending information. A 'complete' status should not conceal an inaccessible investigation or outdated technical agreement. The quality release decision checklist is a reading aid, not a substitute for the applicable QP decision or a universal Annex 16 protocol.

Imported products introduce specific considerations described in Annex 16 section 1.5. The certifying QP must have the required assurance concerning manufacture and testing, and sampling needs to be representative. Where samples are taken in a third country, the Annex describes a technically justified approach supported by quality risk management, assessment of the sampling arrangements and appropriate evidence.

Do not interpret those provisions as a blanket permission to accept any overseas sample or as an unconditional requirement that every sample follow one route. Identify the applicable product, importation arrangement, testing obligations and justification. Keep the basis for reliance available, including the relevant assessments and any conditions. A supplier certificate alone should not be assumed to resolve all importation duties.

Review changes to sampling sites, procedures, handling and transport because they can affect representativeness or integrity. If an unexpected analytical result arises, investigate with the actual sampling history available. This article does not state a universal retest or import-testing exemption; the applicable legal framework and the Annex's detailed conditions must govern the actual arrangement.

Annex 16 section 2 addresses reliance on third-party audits, particularly where outsourced activities have a critical impact on product quality. The certifying QP needs access to appropriate audit information and a documented assessment of its suitability. An audit certificate or brief supplier statement is not automatically equivalent to the report and assessment needed for the particular reliance.

Consider the audit scope, auditor competence, coverage of relevant activities, findings, responses and continued assurance. The Annex discusses a risk-based approach to the frequency and nature of auditing. Avoid inventing a universal annual interval or claiming that any named certification removes the need for GMP assessment. The basis should reflect the actual outsourced operation and its effect on the product.

Document the final assessment and approval of audit reliance as required by the Annex's expectations. If a report is unavailable because of confidentiality, resolve the evidence arrangement rather than assuming the absence is acceptable. A technical agreement should make access practical. Where a significant finding remains unresolved, assess its implication for affected batches and certification rather than leaving it as a disconnected supplier-quality action.

Annex 16 section 3 discusses unexpected deviations from details in the marketing authorization or GMP. It does not authorize routine planned departures from approved requirements or acceptance of known nonconforming product without assessment. Read the section's conditions together, including the requirement that registered specifications be met and the need for a thorough investigation and risk assessment.

Assess potential effects on quality, safety and efficacy and the need for corrective action, regulatory follow-up or stability consideration. The QP must understand the conclusion and its supporting evidence before certification. A generic 'low risk' checkbox does not explain the scientific basis. Likewise, repeating production or testing until an acceptable result appears is not the same as investigating an unexpected deviation.

Recurring events need appropriate evaluation rather than indefinite use of an 'unexpected' label. If the process or authorized conditions require change, use the applicable change and regulatory procedures. This article does not prescribe whether a particular deviation is certifiable; that decision depends on the product, the detailed provisions and the QP's qualified assessment. Do not use an example checklist as predetermined release authority.

Section 1.10 addresses recording QP certification in a register or equivalent document, which is kept current and available to the competent authority. The Annex specifies retention of the certification record for at least five years, while other applicable record duties may also matter. Identify the batch, certification decision and responsible QP so the record can be matched to the actual product history.

Transfer to saleable stock or export follows the applicable certification and controlled arrangements. Section 4 addresses safeguards against uncertified batches reaching saleable stock. Physical segregation, labeling or suitable computerized controls may support that safeguard, but the Annex does not establish that any particular software product provides a validated solution. The actual control must be assessed for its intended use.

If the transfer happens at another site, the written agreement and communication should make the certification status unequivocal. The external record release log can illustrate evidence handoff, but does not confer release authority. A sent email, completed shipment booking or warehouse scan is not equivalent to QP certification unless it faithfully communicates an actual authorized certification decision within the controlled arrangement.

Examine whether an uncertified batch can accidentally move into saleable stock during routine operations, manual corrections, system interruption or site handoff. Identify who may change status and what evidence is required. A procedure that says 'do not ship' is weaker if the practical workflow allows unrestricted selection without a reliable status check. Assess the real process rather than its intended diagram alone.

Where an electronic control is used, verify access, status meaning, relevant record history and the validation evidence appropriate to the intended function. Where a manual control is used, test its visibility and reconciliation. Neither method is inherently sufficient merely because it is electronic or paper. The objective is a reliable safeguard linked to the certification evidence.

Document how exceptions are escalated and how a batch shipped under quarantine remains controlled at the receiving site. The Annex allows such movements under appropriate arrangements; quarantine shipment must not be confused with release to saleable stock. Preserve status relationships across transport and receipt, and make responsibility for the next decision explicit.

Select a batch and retrieve the certification record, relevant confirmations, manufacturing and testing evidence, deviation assessments and stock-transfer record. Ask whether they refer to the same batch and applicable product authorization. Trace one outsourced critical activity to its technical agreement and audit-reliance assessment. This tests the evidence chain rather than only the certification register's appearance.

Review a batch with an unexpected deviation and one involving an imported sample. Ask what the QP relied upon, which matters remained unresolved at the decision time and how the control prevented premature saleable-stock transfer. Potential weaknesses include incomplete responsibility allocation, unsupported audit reliance, ambiguous confirmation-versus-certification terminology, inaccessible investigations and stock status unrelated to the actual certification.

The pharmaceutical sector page and Pharmaceutical Operations Guide provide related context. They do not establish compliance, product certification, QP services or authorization. The manufacturer, authorization holders and relevant qualified personnel remain responsible for their applicable duties. Use the article to improve understanding and evidence design, not to replace product-specific legal and technical review.

A historical certification should be understandable from the evidence available when it was made. Keep the relevant approved versions, confirmations, assessments and certification record connected. A later updated audit report or corrected laboratory document should not silently replace the earlier basis without retaining the change context. Review the effect of new information on affected batches through the applicable quality process.

Test historical retrieval after archival or system migration. Confirm that the QP identity, batch identity, decision, supporting references and stock-transfer relationship remain available. A current release dashboard is not necessarily a historical certification register. This practical check supports defensible record retention without assuming that a readable export alone preserves every required aspect of the original evidence.